[Research](/research) / FdaApprovalPulse

# New FDA PMA Device, NDA, Generic (ANDA), BLA & Drug Supplement Approvals by Sponsor: 2026 statistics from 1,969 public records

**California leads with 110 of 1,969 records (5.6%), ahead of Minnesota with 61 (3.1%) (as of 2026-11-04; source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration)).**

Data as of 2026-11-04 · Compiled by Zalwin from openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration) Copy citation

Work with the records behind these figures: all 1,969 FdaApprovalPulse records with source links, as one CSV.

Download all 1,969 records (CSV) — $4.99 → [Free sample: 3 records (CSV)](/v1/verticals/fdaapprovalpulse/records.csv) [Search the records free →](/v/fdaapprovalpulse?channel=pseo#vt-out)

Double opt-in: we send one confirmation email when digests start; nothing else until you confirm. One-click unsubscribe.

## Key findings

- Zalwin's FdaApprovalPulse dataset holds 1,969 FdaApprovalPulse records dated 2026-05-01 to 2026-10-30 (as of 2026-11-04; source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration)). [#](#finding-1)
- California leads with 110 of 1,969 records (5.6%), ahead of Minnesota with 61 (3.1%) (as of 2026-11-04; source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration)). [#](#finding-2)
- The most common approval type is Drug labeling or REMS supplement: 1,180 of 1,969 records (59.9%) (as of 2026-11-04; source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration)). [#](#finding-3)
- 222 of 1,969 records (11.3%) are dated within the 30 days before 2026-11-04 (source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration)). [#](#finding-4)
- In California, the leading approval type is PMA supplement (device change) with 105 of 110 records (95.5%) (as of 2026-11-04; source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration)). [#](#finding-5)

## FdaApprovalPulse records by state

| Group | Records | Share |
|---|---|---|
| California | 110 | 5.6% |
| Minnesota | 61 | 3.1% |
| Massachusetts | 37 | 1.9% |
| Oregon | 20 | 1.0% |
| Arizona | 18 | 0.9% |
| Texas | 18 | 0.9% |
| Illinois | 9 | 0.5% |
| Maryland | 9 | 0.5% |
| Tennessee | 8 | 0.4% |
| Pennsylvania | 7 | 0.4% |
| Florida | 6 | 0.3% |
| Washington | 6 | 0.3% |
| Missouri | 5 | 0.3% |
| Wisconsin | 5 | 0.3% |
| Colorado | 4 | 0.2% |

## FdaApprovalPulse records by approval type

| Group | Records | Share |
|---|---|---|
| Drug labeling or REMS supplement | 1,180 | 59.9% |
| PMA supplement (device change) | 367 | 18.6% |
| Generic drug approval (ANDA) | 196 | 10.0% |
| Drug efficacy supplement (new indication or use) | 77 | 3.9% |
| Drug manufacturing (CMC) supplement | 55 | 2.8% |
| New drug application (NDA) | 41 | 2.1% |
| PMA original approval (new class III device) | 24 | 1.2% |
| Biologic license (BLA) | 17 | 0.9% |
| Other drug supplement | 12 | 0.6% |

## Methodology and data provenance

- Sample: 1,969 public records dated 2026-05-01 to 2026-10-30; illustrative samples excluded.

- Source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration). Refreshed automatically about every 24 hours; figures above are as of 2026-11-04.

- Shares are of all records in the dataset; totals and medians use only records with a stated amount.

- Organization-level data only. Informational; verify individual records at the official source.

### Cite this study

Zalwin Research, "FdaApprovalPulse statistics" (data as of 2026-11-04), https://zalwin.com/research/fdaapprovalpulse

Copy citation

[Search the FdaApprovalPulse records](/v/fdaapprovalpulse) [Browse by state and category](/hub/fdaapprovalpulse)